Effectiveness of finerenone for proteinuria reduction in IgA nephropathy: A multicenter target trial emulation
Year: 2026
Type: article
Study design: Observational Study
Abstract: Background Finerenone, a non-steroidal mineralocorticoid receptor antagonist, reduces proteinuria in diabetic kidney disease. Real-world evidence in IgA nephropathy (IgAN) remains limited to single-center studies that are often mixed with immunosuppression and susceptible to immortal time bias. Methods We emulated a target trial using data from a multicenter retrospective registry across 25 hospitals in China (2022–2026). Eligible adults had biopsy-proven IgAN, persistent proteinuria > 0.5 g/day despite stable renin-angiotensin system (RAS) inhibitor therapy, and eGFR ≥15 mL/min/1.73 m². Using the clone-censor-weight (CCW) approach with a 3-month grace period, we compared finerenone initiation with non-initiation. The primary outcome was a composite of ≥ 40% reduction in proteinuria from baseline with stable kidney function. We additionally performed marginal structural model (MSM) analyses, including an exploratory dose analysis, eGFR trajectory analysis, and prespecified subgroup analyses. Results Among 238 patients, 141 received finerenone, most at an initial dose of 10 mg daily. Of these, 119 started treatment within the 3-month grace period. This initiation strategy was associated with a higher probability of the primary composite outcome (hazard ratio [HR], 1.51; 95% CI, 1.17 to 1.96; absolute risk difference at 12 months, 22.3%; 95% CI, 5.9% to 38.7%). The association was directionally consistent in MSM analyses (HR, 1.83; 95% CI, 1.29 to 2.59). Monthly eGFR slopes did not differ between strategies (−0.05 mL/min/1.73 m² per month; P = 0.82). Hyperkalemia occurred in 4 patients, including one in the finerenone initiation strategy. Conclusion In this multicenter target-trial emulation, finerenone initiation as an adjunct to background RAS inhibitors was associated with clinically meaningful proteinuria reduction in patients with IgAN under current supportive care. These data may help inform real-world use, including up-titration to 20 mg when serum potassium and kidney function permit.
Source: Clinical Kidney Journal
DOI: 10.1093/ckj/sfag401
Institutions: Peking University First Hospital, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an Jiaotong University, Sichuan University, West China Hospital of Sichuan University, First Affiliated Hospital of Xinjiang Medical University, Sun Yat-sen University, Eighth Affiliated Hospital of Sun Yat-sen University, Southern Medical University Shenzhen Hospital, Peking University People's Hospital, Hubei University of Chinese Medicine, Hubei Provincial Hospital of Traditional Chinese Medicine, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, Southwest Medical University, Affiliated Hospital of Southwest Medical University, Sir Run Run Shaw Hospital, Zhejiang University, Hebei Medical University, Third Hospital of Hebei Medical University
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,335
OpenAlex ID: W7236710395
